Pharmaceutical deals in 2025 focus on late-stage assets and strategic differentiation

The pharmaceutical industry’s dealmaking regained momentum in 2025 as global drugmakers pursued acquisitions to shore up pipelines, offset looming patent expiries and accelerate access to differentiated science. A wave of high‑value transactions , spanning neuroscience, respiratory, rare disease, vaccines, metabolic and cardiovascular therapies , reflected a strategic shift away from scale alone towards purchases that buy late‑stage assets, platform technologies and clear clinical advantage.

At the top of the calendar year, Johnson & Johnson completed its roughly $14.6 billion acquisition of Intra‑Cellular Therapies, adding CAPLYTA (lumateperone), an FDA‑approved oral therapy for schizophrenia and bipolar depression, together with a clinical‑stage neuroscience programme including ITI‑1284. According to a company press release, J&J said the deal strengthens its neuroscience leadership by combining an approved product with assets in generalised anxiety disorder and Alzheimer’s disease‑related psychosis. Industry observers described the move as emblematic of 2025’s buyer preference for well‑validated CNS assets with near‑term commercial potential.

Merck’s $10 billion purchase of UK‑based Verona Pharma underlined the same logic in respiratory care. The acquisition, which grants Merck rights to Ohtuvayre® (ensifentrine), a first‑in‑class maintenance treatment for COPD, was presented by Merck leadership as a way to diversify its cardio‑pulmonary portfolio ahead of potential revenue pressures from forthcoming patent cliffs. Financial and news outlets reported the deal as a strategic bet on differentiated symptomatic therapies that can sustain sales into the next decade.

Sanofi drove a multi‑deal strategy in 2025 focused on vaccines, rare diseases and oncology. Its headline purchase of Blueprint Medicines for about $9.5 billion bolstered Sanofi’s position in precision oncology and mast cell disorders with medicines such as Ayvakit/Ayvakyt (avapritinib) and next‑generation KIT inhibitors in development. Sanofi’s separate acquisition of Dynavax Technologies for roughly $2.2 billion added HEPLISAV‑B and an adjuvant platform, signalling a renewed corporate emphasis on adult immunisation and steady, platform‑driven vaccine growth rather than one‑off blockbuster bets.

Novartis pursued targeted, science‑led deals rather than broadscale consolidation. Its completion of the Anthos Therapeutics acquisition, valued at up to $3.1 billion, secured full rights to abelacimab, a late‑stage monoclonal antibody against factor XI intended to prevent thrombosis with a potentially lower bleeding risk. Novartis also bought Tourmaline Bio for about $1.4 billion to deepen its pipeline in inflammation‑driven cardiovascular disease, reflecting a strategy of investing in assets with precise mechanisms and clear clinical rationale.

Roche’s definitive agreement to acquire 89bio for about $2.4 billion reinforced interest in metabolic, renal and cardiovascular medicines: 89bio’s pegozafermin, aimed at overweight, obesity and metabolic dysfunction such as MASH, was framed by Roche as complementary to its CVRM efforts and an opportunity for future combination approaches with incretins. Biotech consolidation in platform technologies also saw BioNTech acquire CureVac for about $1.25 billion, a deal widely portrayed as a strategic consolidation of mRNA talent, intellectual property and manufacturing capability to underpin long‑term cancer and immunotherapy ambitions rather than short‑term commercial pursuits.

Deal activity extended beyond the largest western majors. Torrent Pharmaceuticals’ acquisition of a controlling stake in JB Chemicals for a reported valuation of around ₹25,689 crore was one of India’s largest pharma transactions of 2025, strengthening Torrent’s domestic formulations franchise across cardiology, gastroenterology and pain management and folding in JB’s hospital and export businesses. Industry commentary characterised the move as part of accelerating consolidation in regional markets, where scale and established brand portfolios matter for sustained growth.

Smaller, science‑focused purchases rounded out the year. Eli Lilly’s roughly $1 billion acquisition of SiteOne Therapeutics enhanced its pain pipeline with selective sodium‑channel inhibitors aimed at chronic and neuropathic pain, reflecting a broader industry search for non‑addictive alternatives to opioids. Roche, Sanofi and others similarly targeted specialist biotechs with assets that could be rapidly advanced through late‑stage development or paired with incumbent portfolios.

Several common drivers underpinned the 2025 M&A surge. Rising R&D costs and regulatory complexity made external innovation an attractive shortcut to late‑stage assets; buyers sought to shorten development timelines by acquiring programmes with human proof‑of‑concept. Biotech firms with robust clinical data benefited from renewed buyer appetite and, in many cases, secured favourable exits. At the same time, the prospect of major product patent expiries , and the revenue volatility those create , encouraged large pharma to prioritise deals that deliver differentiated, defendable franchises.

The pattern of transactions also highlighted tactical diversification: acquisitions of vaccines and adjuvant platforms reflected long‑term revenue stability; purchases in rare disease and precision oncology offered high‑value, targeted markets; and deals in metabolic and cardiopulmonary disease aimed to capture broad, chronic‑care patient populations. Analysts noted that companies increasingly weighed scientific fit and near‑term commercialisability over sheer portfolio expansion.

Not all observers were unequivocally optimistic. Some commentators cautioned about integration risks, potential overlap with existing R&D pipelines and the challenge of converting acquired assets into sustainable, long‑term growth. Nevertheless, the breadth and scale of 2025’s pharmaceutical M&A activity reshaped competitive dynamics across major therapeutic areas and signalled a renewed industry conviction that carefully chosen acquisitions, rather than in‑house discovery alone, will be central to sustaining innovation and commercial success in the coming decade.